|
|
Blueprint Medicines Corporation (BPMC) |
|
Price: $49.3300
$-0.19 
-0.384%
|
| Day's High:
| $49.99
| Week Perf:
| -3.9 %
|
| Day's Low: |
$ 48.16 |
30 Day Perf: |
-0.64 % |
| Volume (M): |
412 |
52 Wk High: |
$ 68.63 |
| Volume (M$): |
$ 20,334 |
52 Wk Avg: |
$50.46 |
| Open: |
$49.35 |
52 Wk Low: |
$37.82 |
|
|
| Market Capitalization (Millions $) |
2,985 |
| Shares
Outstanding (Millions) |
61 |
| Employees |
582 |
| Revenues (TTM) (Millions $) |
202 |
| Net Income (TTM) (Millions $) |
-554 |
| Cash Flow (TTM) (Millions $) |
-97 |
| Capital Exp. (TTM) (Millions $) |
10 |
Blueprint Medicines Corporation
Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing precision therapies for patients with genetically defined diseases. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts. Blueprint Medicines focuses on developing small molecule drugs that target specific genetic abnormalities or pathways associated with diseases.
The company's main area of focus is targeted oncology, with a particular emphasis on developing therapies for patients with gastrointestinal stromal tumors (GIST) and other solid tumor types. Blueprint's lead product, Ayvakit (avapritinib), is a small molecule kinase inhibitor that has been approved by the US FDA for the treatment of patients with GIST who have a specific mutation called PDGFRA exon 18.
Blueprint Medicines has several other programs in development, including BLU-285, a potent inhibitor of KIT and PDGFRA kinase mutations that are resistant to current therapies. The company is also developing an investigational drug, BLU-667, which targets RET, a genetic driver of non-small cell lung cancer and thyroid cancer.
In addition to oncology, Blueprint Medicines is also developing therapies for patients with rare genetic diseases including fibrodysplasia ossificans progressiva (FOP) and achondroplasia, which are both caused by specific genetic mutations.
Notably, Blueprint Medicines has established partnerships with other biopharmaceutical companies, including Roche and CStone Pharmaceuticals, for the development and commercialization of its investigational drug candidates.
Overall, Blueprint Medicines Corporation is a leading biopharmaceutical company that is dedicated to developing precision medicines for patients with genetically defined diseases. Through its innovative approach to drug discovery and development, Blueprint Medicines has the potential to transform the lives of patients living with cancer and rare genetic diseases.
Company Address: 45 Sidney Street Cambridge 2139 MA
Company Phone Number: 374-7580 Stock Exchange / Ticker: NASDAQ BPMC
| BPMC is expected to report next financial results on October 31, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Cannapharmarx Inc
The first quarter of 2023 has shown significant promise for Cannapharmarx Inc, a major player in the pharmaceutical preparations industry. While the company has not revealed any top-line figures yet, industry observers are examining the operating shortfall of $-0.720277 million, shedding light on the positive performance of the firm during this period. By comparing it to previous quarters and assessing other growth indicators, we can anticipate a bullish outlook for Cannapharmarx Inc in the near future.
Reduced Losses and Growing Revenue:
In the first quarter of 2022, Cannapharmarx Inc experienced an operating shortfall of $-0.715558 million. However, with effective cost-cutting measures and revenue growth strategies, the company has managed to improve its financial performance in Q1 2023. The company's losses of $-2.072 million in the first quarter of 2022 have been reduced to $-1.413 million, showcasing a significant improvement in their bottom line. This reduction of losses is indicative of a more efficient and profitable operation.
|
|
Benitec Biopharma Inc
Financial News Report: Benitec Biopharma Inc Reports Loss in Fiscal Year 2023
Benitec Biopharma Inc, a major pharmaceutical preparations company, recently released its financial results for the fiscal interval ending June 30, 2023. The company reported a net loss of $-4.661 million, compared to a deficit of $-5.067 million in the corresponding reporting season a year ago.
In terms of earnings per share (EPS), Benitec Biopharma Inc experienced a decline from $-0.16 per share in the previous reporting season to $-0.17 per share in the current period. However, this is an improvement compared to the earnings of $-0.62 per share a year before the reporting season.
|
|
Kintara Therapeutics Inc
Bearish Outlook for Kintara Therapeutics Inc as Fourth Quarter Earnings Paint a Bleak Picture
The fourth quarter earnings report for Kintara Therapeutics Inc (KTRA) has sent shockwaves through the market as the pharmaceutical preparations sector advisors begin to analyze the data. With an operating profit of $3.349 million, KTRA has failed to disclose its revenue for the April to June 2023 financial reporting period. However, comparisons with the previous year's performance highlight a worrying trend.
In the fourth quarter of 2022, KTRA recorded a significantly higher operating profit of $5.458 million, indicating a sharp decline in operating earnings by -38.64%. This decline is a cause for concern as it reflects a substantial decrease in the company's efficiency and overall financial performance. Furthermore, the management has failed to address the issue of diminishing returns, leading to a net deficit of $-14.66 million and a troubling revenue of $0.00 million in the fiscal period 2023.
|
|
Integrated Biopharma Inc
Integrated Biopharma Inc recently released its financial results for the fiscal period ending June 30, 2023. The report highlights a decrease in revenue, net earnings, as well as a decline in operating and net margins. Additionally, the company's stockpiles remain below the previous year's level. This article aims to outline the key facts from the financial results and provide an analysis of Integrated Biopharma Inc's performance.
Financial Results Overview:
1. Earnings per Share (EPS): In the fiscal period ending June 30, 2023, Integrated Biopharma Inc recorded an EPS of $0.00 per share, compared to $0.05 per share in the same period a year ago. This figure also remained consistent with the preceding reporting period.
|
|
Rezolute Inc
Despite some positive momentum in recent weeks, Rezolute Inc (RZLT) remains an overlooked player in the Major Pharmaceutical Preparations sector. The company's financial numbers paint a gloomy picture, indicating significant operating shortfalls and a net deficit.
In the fourth quarter of 2023, Rezolute Inc reported an operating shortfall of $-14.238 million, demonstrating a worsening financial situation. Although the company has not disclosed its revenue, it is clear that its current revenue figures are not helping to alleviate concerns. Comparing it to the fourth quarter of 2022, where Rezolute Inc reported an operating shortfall of $-11.3 million, it is evident that the company's financial woes have only worsened over time.
The shortfall of $-12.728 million reported in the comparable three months preceding last year is also a cause for concern. The fact that this figure increased from $-9.423 million is alarming and suggests a lack of progress in addressing financial challenges. Additionally, the company reported a net deficit of $-51.79 million, further highlighting its troubled financial state.
|
| Per Share |
Current |
| Earnings (TTM) |
-9.17 $ |
| Revenues (TTM) |
3.34 $
|
| Cash Flow (TTM) |
- |
| Cash |
11.94 $
|
| Book Value |
5.14 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-9.17 $
|
| Revenues (TTM) |
3.34 $ |
| Cash Flow (TTM) |
- |
| Cash |
11.94 $
|
| Book Value |
5.14 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
